Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueShares Outstanding (Weighted Average)Tax Rate
Others
Ratios

NewGenIvf (NIVF) Net Income towards Common Stockholders: 2021-2024

Historic Net Income towards Common Stockholders for NewGenIvf (NIVF) over the last 4 years, with Dec 2024 value amounting to -$474,101.

  • NewGenIvf's Net Income towards Common Stockholders rose 55297.35% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year change of. This contributed to the annual value of -$474,101 for FY2024, which is 537.29% down from last year.
  • NewGenIvf's Net Income towards Common Stockholders amounted to -$474,101 in FY2024, which was down 537.29% from $108,418 recorded in FY2023.
  • In the past 5 years, NewGenIvf's Net Income towards Common Stockholders ranged from a high of $135,847 in FY2022 and a low of -$474,101 during FY2024.
  • Over the past 3 years, NewGenIvf's median Net Income towards Common Stockholders value was $108,418 (recorded in 2023), while the average stood at -$76,612.
  • In the last 5 years, NewGenIvf's Net Income towards Common Stockholders soared by 198.06% in 2022 and then plummeted by 537.29% in 2024.
  • Over the past 4 years, NewGenIvf's Net Income towards Common Stockholders (MRY) stood at -$138,532 in 2021, then skyrocketed by 198.06% to $135,847 in 2022, then dropped by 20.19% to $108,418 in 2023, then tumbled by 537.29% to -$474,101 in 2024.
  • Its Net Income towards Common Stockholders stands at -$474,101 for FY2024, versus $108,418 for FY2023 and $135,847 for FY2022.